Timothy L. Moore - Apr 24, 2023 Form 4 Insider Report for Allogene Therapeutics, Inc. (ALLO)

Role
Chief Technical Officer
Signature
/s/Lillian Smith, Attorney-in-Fact
Stock symbol
ALLO
Transactions as of
Apr 24, 2023
Transactions value $
$0
Form type
4
Date filed
4/26/2023, 05:20 PM
Previous filing
Jan 18, 2023
Next filing
Jun 9, 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALLO Common Stock Award $0 +186K $0.00 186K Apr 24, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALLO Stock Option (Right to Buy) Award $0 +831K $0.00 831K Apr 24, 2023 Common Stock 831K $5.37 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the stock option shall vest on April 24, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter.